The introduction of multiparametric MRI (mpMRI) has improved the diagnosis and risk stratification of intermediate and high-risk prostate cancer. In addition to diagnosis, mpMRI has increasingly become a useful tool for monitoring the prostate cancer risk of patients on active surveillance (AS) programmes.
Long-term data indicates that there is no oncological benefit for AS programmes for patients diagnosed with intermediate risk prostate cancer. Further, there is increasing evidence that PI-RADS 4 lesion on mpMRI correlates with intermediate and high-risk prostate cancer.